NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of Lu-DOTATATE Peptide Receptor Radionuclide Therapy.
作者信息
Hope Thomas A, Bodei Lisa, Chan Jennifer A, El-Haddad Ghassan, Fidelman Nicholas, Kunz Pamela L, Mailman Josh, Menda Yusuf, Metz David C, Mittra Erik S, Pryma Daniel A, Reidy-Lagunes Diane L, Singh Simron, Strosberg Jonathan R
机构信息
Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California
Department of Radiology, San Francisco VA Medical Center, San Francisco, California.
出版信息
J Nucl Med. 2020 Feb;61(2):222-227. doi: 10.2967/jnumed.119.240911.
Abstract
摘要
相似文献
1
NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of Lu-DOTATATE Peptide Receptor Radionuclide Therapy.NANETS/SNMMI关于Lu- DOTATATE肽受体放射性核素治疗患者选择和合理使用的共识声明。
J Nucl Med. 2020 Feb;61(2):222-227. doi: 10.2967/jnumed.119.240911.
2
NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with Lu-DOTATATE.基于 Lu-DOTATATE 的生长抑素受体靶向肽受体放射性核素治疗的 NANETS/SNMMI 操作标准。
J Nucl Med. 2019 Jul;60(7):937-943. doi: 10.2967/jnumed.118.230607.
3
In Vivo Instability of Lu-DOTATATE During Peptide Receptor Radionuclide Therapy.肽受体放射性核素治疗期间镥-奥曲肽在体内的不稳定性
J Nucl Med. 2020 Sep;61(9):1337-1340. doi: 10.2967/jnumed.119.237818. Epub 2020 Jan 31.
4
Sequential Duo-Peptide Receptor Radionuclide Therapy With Indigenous 90Y-DOTATATE and 177Lu-DOTATATE in Large-Volume Neuroendocrine Tumors: Posttherapy Bremsstrahlung and PET/CT Imaging Following 90Y-DOTATATE Treatment.大体积神经内分泌肿瘤的内源性 90Y-DOTATATE 和 177Lu-DOTATATE 序贯双肽受体放射性核素治疗：90Y-DOTATATE 治疗后放射性核素 Bremsstrahlung 及 PET/CT 显像
Clin Nucl Med. 2020 Sep;45(9):714-715. doi: 10.1097/RLU.0000000000003182.
5
Excellent Response to 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in a Patient With Progressive Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation After 177Lu-PSMA Therapy.177Lu-PSMA 治疗后进展性转移性去势抵抗性前列腺癌伴神经内分泌分化患者对 177Lu-DOTATATE 肽受体放射性核素治疗的良好反应。
Clin Nucl Med. 2019 Nov;44(11):876-878. doi: 10.1097/RLU.0000000000002780.
6
Long-term results and tolerability of tandem peptide receptor radionuclide therapy with Y/Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study.Y/Lu-DOTATATE串联肽受体放射性核素治疗神经内分泌肿瘤的长期疗效及耐受性与原发部位的关系：一项10年研究
Ann Nucl Med. 2017 Jun;31(5):347-356. doi: 10.1007/s12149-017-1163-6. Epub 2017 Mar 18.
7
Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors.在生长抑素表达型神经内分泌肿瘤患者中，经区域性肝动脉栓塞治疗后应用 177Lu-DOTATATE 肽受体放射性核素疗法的安全性和有效性。
Clin Nucl Med. 2017 Nov;42(11):822-828. doi: 10.1097/RLU.0000000000001818.
8
Combined Lu-DOTATATE Peptide Receptor Radionuclide Therapy and Platinum-Based Chemotherapy in Recurrent, Metastatic Sinonasal Neuroendocrine Carcinoma: A Promising Therapeutic Option.联合 Lu-DOTATATE 肽受体放射性核素治疗与铂类化疗治疗复发性、转移性鼻腔鼻窦神经内分泌癌：一种有前途的治疗选择。
J Nucl Med Technol. 2020 Sep;48(3):292-294. doi: 10.2967/jnmt.119.237354. Epub 2020 May 1.
9
Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors.Lu-DOTATATE 肽受体放射性核素治疗后持续性血液学功能障碍：胃肠胰神经内分泌肿瘤患者的发生率、病程和预测因素。
J Nucl Med. 2018 Mar;59(3):452-458. doi: 10.2967/jnumed.117.189712. Epub 2017 Aug 3.
10
Guidance on Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division.基于单核医学科经验的镥- DOTATATE肽受体放射性核素治疗指南。
J Nucl Med Technol. 2018 Sep;46(3):237-244. doi: 10.2967/jnmt.118.209148. Epub 2018 Aug 3.
引用本文的文献
1
Nutritional Management of Functioning GEP-NENs.功能性胃肠胰神经内分泌肿瘤的营养管理
Nutrients. 2025 Jun 30;17(13):2175. doi: 10.3390/nu17132175.
2
Association of integrated biomarkers and progression-free survival prediction in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy.接受[177Lu]Lu-DOTA-TATE治疗的胃肠胰神经内分泌肿瘤患者中综合生物标志物与无进展生存预测的关联
Theranostics. 2025 May 25;15(13):6444-6453. doi: 10.7150/thno.112588. eCollection 2025.
3
Last decade of advances in gastric neuroendocrine tumors: Innovations, challenges, and future directions.胃神经内分泌肿瘤近十年的进展：创新、挑战与未来方向
World J Clin Oncol. 2025 May 24;16(5):104577. doi: 10.5306/wjco.v16.i5.104577.
4
Comparison of the Hematotoxicity of PRRT with Lutathera and Locally Manufactured Lu-HA-DOTATATE in Patients with Neuroendocrine Tumors and the Impact of Different Application Intervals.肽受体放射性核素治疗（PRRT）与镥[177Lu]奥曲肽（Lutathera）及国产镥[177Lu]奥曲肽（Lu-HA-DOTATATE）对神经内分泌肿瘤患者血液毒性的比较及不同应用间隔的影响
Cancers (Basel). 2025 Apr 24;17(9):1423. doi: 10.3390/cancers17091423.
5
Outcome of Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Progressive Metastatic Neuroendocrine Tumors from a Tertiary Care Center.来自三级医疗中心的Lu-DOTATATE肽受体放射性核素治疗进展性转移性神经内分泌肿瘤的疗效
Indian J Endocrinol Metab. 2024 Nov-Dec;28(6):601-610. doi: 10.4103/ijem.ijem_372_23. Epub 2024 Dec 30.
6
The role of combined FDG and SST PET/CT in neuroendocrine tumors.氟代脱氧葡萄糖（FDG）与生长抑素（SST）联合正电子发射断层显像/计算机断层扫描（PET/CT）在神经内分泌肿瘤中的作用
J Neuroendocrinol. 2025 Mar;37(3):e13474. doi: 10.1111/jne.13474. Epub 2024 Nov 22.
7
Assessment of response to PRRT including anatomical and molecular imaging as well as novel biomarkers.评估对肽受体放射性核素治疗（PRRT）的反应，包括解剖学和分子成像以及新型生物标志物。
J Neuroendocrinol. 2025 Mar;37(3):e13461. doi: 10.1111/jne.13461. Epub 2024 Nov 9.
8
β1600 Q.Clear Digital Reconstruction of [Ga]Ga-DOTANOC PET/CT Improves Image Quality in NET Patients.β1600 Q. [镓]镓-多他胺PET/CT的清晰数字重建改善了神经内分泌肿瘤患者的图像质量。
J Clin Med. 2024 Jun 29;13(13):3841. doi: 10.3390/jcm13133841.
9
Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0.使用放射性标记生长抑素受体配体的脑膜瘤诊断和治疗（治疗学）的 EANM/EANO/RANO/SNMMI 联合实践指南/程序标准：第 1.0 版。
Eur J Nucl Med Mol Imaging. 2024 Oct;51(12):3662-3679. doi: 10.1007/s00259-024-06783-x. Epub 2024 Jun 20.
10
Repeat Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors: A NET Center of Excellence Experience.重复肽受体放射性核素治疗神经内分泌肿瘤：一个神经内分泌肿瘤卓越中心的经验。
J Gastrointest Cancer. 2024 Sep;55(3):1165-1170. doi: 10.1007/s12029-024-01065-z. Epub 2024 May 23.
本文引用的文献
1
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with Lu-Dotatate: an analysis of the NETTER-1 study.肝脏肿瘤负荷、碱性磷酸酶升高及靶病灶大小对镥[177Lu]奥曲肽治疗结局的影响：NETTER-1研究分析
Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2372-2382. doi: 10.1007/s00259-020-04709-x. Epub 2020 Mar 2.
2
In-Pentetreotide Scintigraphy Versus Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden.五肽胃泌素闪烁显像与 Ga-DOTATATE PET：对 Krenning 评分的影响和肿瘤负荷的作用。
J Nucl Med. 2019 Sep;60(9):1266-1269. doi: 10.2967/jnumed.118.223016. Epub 2019 Mar 8.
3
Characterization, Prognosis, and Treatment of Patients With Metastatic Lung Carcinoid Tumors.转移性肺类癌肿瘤患者的特征、预后和治疗。
J Thorac Oncol. 2019 Jun;14(6):993-1002. doi: 10.1016/j.jtho.2019.02.002. Epub 2019 Feb 13.
4
Biodistribution and radiation dose estimates for Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors.镓-DOTA-JR11 在转移性神经内分泌肿瘤患者中的生物分布和辐射剂量估算。
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):677-685. doi: 10.1007/s00259-018-4193-y. Epub 2018 Oct 29.
5
Efficacy and Safety of High-Specific-Activity I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma.高比活度碘-间碘苄胍治疗晚期嗜铬细胞瘤或副神经节瘤的疗效和安全性。
J Nucl Med. 2019 May;60(5):623-630. doi: 10.2967/jnumed.118.217463. Epub 2018 Oct 5.
6
Salvage peptide receptor radionuclide therapy with [Lu-DOTA,Tyr]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours.[Lu-DOTA,Tyr]奥曲肽挽救性肽受体放射性核素治疗支气管和胃肠胰腺神经内分泌肿瘤。
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):704-717. doi: 10.1007/s00259-018-4158-1. Epub 2018 Sep 28.
7
Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.《3 级神经内分泌肿瘤的肽受体放射性核素治疗：69 例患者的安全性和生存分析》
J Nucl Med. 2019 Mar;60(3):377-385. doi: 10.2967/jnumed.118.215848. Epub 2018 Aug 16.
8
NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.NCCN 指南解读：神经内分泌和肾上腺肿瘤，第 2.2018 版。
J Natl Compr Canc Netw. 2018 Jun;16(6):693-702. doi: 10.6004/jnccn.2018.0056.
9
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With Lu-Dotatate in the Phase III NETTER-1 Trial.在 III 期 NETTER-1 试验中，接受 Lu-Dotatate 治疗的进展性中肠神经内分泌肿瘤患者的生活质量与健康相关。
J Clin Oncol. 2018 Sep 1;36(25):2578-2584. doi: 10.1200/JCO.2018.78.5865. Epub 2018 Jun 7.
10
Results and adverse events of personalized peptide receptor radionuclide therapy with Yttrium and Lutetium in 1048 patients with neuroendocrine neoplasms.1048例神经内分泌肿瘤患者接受钇和镥个体化肽受体放射性核素治疗的结果及不良事件
Oncotarget. 2018 Feb 15;9(24):16932-16950. doi: 10.18632/oncotarget.24524. eCollection 2018 Mar 30.
Zotero 插件